Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2002-06-14
2010-02-23
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07666411
ABSTRACT:
Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG.3). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.
REFERENCES:
patent: 5614191 (1997-03-01), Puri et al.
patent: 5830453 (1998-11-01), Badr et al.
patent: 5965401 (1999-10-01), Chang et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6140076 (2000-10-01), Adema et al.
patent: 6143871 (2000-11-01), Bonnefoy et al.
patent: 6274338 (2001-08-01), Glimcher
patent: 6358508 (2002-03-01), Ni et al.
patent: 6518061 (2003-02-01), Puri et al.
patent: 6696545 (2004-02-01), Buelow et al.
patent: 2002/0042387 (2002-04-01), Raz et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 2004/0023337 (2004-02-01), Heavner et al.
patent: 2004/0043921 (2004-03-01), Bonnefoy et al.
patent: 2002315115 (2009-01-01), None
patent: WO 00/02583 (2000-01-01), None
patent: WO 00/02923 (2000-01-01), None
patent: WO 00/64944 (2000-11-01), None
patent: WO 01/82960 (2001-11-01), None
patent: WO 03/080675 (2003-10-01), None
patent: 2005/0375 (2006-08-01), None
Kawada et al., World J. Gastroenterol., 2007, 14: 5581-5593.
Heller et al., Immunity, 2002, 17: 629-638.
Bost et al. “In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice”Immunol. 87:633-64 (1996).
Chiaramonte et al. “IL-13 is a key regulator cytokine for Th2 cell-mediated pulmonary granuloma rormation and IgE responses induced byS. mansonieggs”J. Immunol. 162(2):920-930 (1999).
Grünig et al. “Requirement for IL-13 independently of IL-4 in experimental asthma”Science282:2261-2263 (Dec. 18, 1998).
Hans et al. “Interleukin 12 induced interferon-γ increases inflammation in acute dextran sulfate sodium induced colitis in mice”Eur. Cytokine Netw11:67-74 (Mar. 2000).
Shalaby et al. “In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and Interleukin-2”J Interferon Research5:571-581 (1985).
Verdú et al. “Modulatory effects of estrogen in two murine models of experimental colitis”Am J Physiol Gastrointest Liver Physiol283:G27-G36 (2002).
Balk, S. P., Bleicher, P. A., and Terhorst, C. (1989). Isolation and characterization of a cDNA and gene coding for a fourth CD1 molecule. Proc Natl Acad Sci U S A 86, 252-256.
Bendelac, A. (1995). Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J Exp Med 182, 2091-2096.
Bleicher, P. A., Balk, S. P., Hagen, S. J., Blumberg, R. S., Flotte, T. J., and Terhorst, C. (1990). Expression of murine CD1 on gastrointestinal epithelium. Science 250, 679-682.
Blumberg, R. S., Terhorst, C., Bleicher, P., McDermott, F. V., Allan, C. H., Landau, S. B., Trier, J. S., and Balk, S. P. (1991). Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J Immunol 147, 2518-2524.
Boirivant, M., Fuss, I. J., Chu, A., and Strober, W. (1998). Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 188, 1929-1939.
Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM, Porcelli SA, Nickoloff BJ. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol. Oct. 1, 2000;165(7):4076-85.
Brown, KD, Zurawski SM, Mosmann TR, Zurawski G. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processesJ. Immunol. 142 (2), 679-687 (1989).
Brown, M. A., and Hural, J. (1997). Functions of IL-4 and control of its expression. Crit Rev Immunol 17, 1-32.
Brown, TE, Bankhurst AD, Strickland RG. Natural killer cell function and lymphocyte subpopulation profiles in inflammatory bowel disease. J Clin Lab Immunol. Jul. 1983;11(3):113-7.
Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. Nov. 1998;4(4):285-90.
Ceponis, P. J., Botelho, F., Richards, C. D., and McKay, D. M. (2000). Interleukins 4 and 13 increase intestinal epithelial permeability by a phosphatidylinositol 3-kinase pathway. Lack of evidence for STAT 6 involvement. J Biol Chem 275, 29132-29137.
Chen, H., and Paul, W. E. (1997). Cultured NK1.1+ CD4+ T cells produce large amounts of IL-4 and IFN- gamma upon activation by anti-CD3 or CD1. J Immunol 159, 2240-2249.
Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., and Taniguchi, M. (1997). Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278, 1623-1626.
del Mar Cabrera M, Valle J, Pajares JM, Romero I, Zomeno M, Mate J. Expression of the Kp43 (CD 94) receptor by natural killer (NK) cells in ulcerative colitis. Hepatogastroenterology. Sep.-Oct. 2001;48(41):1316-20.
Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology. Jul. 1997;113(1):118-26.
Dolganov, et al. “Coexpression of the interleukin-13 and interleukin-4 genes correlates with their physical linkage in the cytokine gene cluster on human chromosome 5q23-31”Blood87 (8), 3316-3326 (1996).
Donaldson, D. D., Whitters, M. J., Fitz, L. J., Neben, T. Y., Finnerty, H., Henderson, S. L., O'Hara, R. M., Jr., Beier, D. R., Turner, K. J., Wood, C. R., and Collins, M. (1998). The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161, 2317-2324.
Fiocchi C, Tubbs RR, Youngman KR. Human intestinal mucosal mononuclear cells exhibit lymphokine-activated killer cell activity. Gastroenterology. Mar. 1985;88(3):625-37.
Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., and O'Garra, A. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146, 3444-3451.
Fort, M. M., Cheung, J., Yen, D., Li, J., Zurawski, S. M., Lo, S., Menon, S., Clifford, T., Hunte, B., Lesley, R., et al. (2001). IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15, 985-995.
Fuss, I. J., Neurath, M., Boirivant, M., Klein, J. S., de la Motte, C., Strong, S. A., Fiocchi, C., and Strober, W. (1996). Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157, 1261-1270.
Ginsburg CH, Dambrauskas JT, Ault KA, Falchuk ZM. Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect. Gastroenterology. Oct. 1983;85(4):846-51.
Gumperz, J. E., Roy, C., Makowska, A., Lum, D., Sugita, M., Podrebarac, T., Koezuka, Y., Porcelli, S. A., Cardell, S., Brenner, M. B., and Behar, S. M. (2000). Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12, 211-221.
Hayakawa, K., Lin, B. T., and Hardy, R. R. (1992). Murine thymic CD4+ T cell subsets: a subset (Thy0) that secretes diverse cytokines and overexpresses the V beta 8 T cell receptor gene family. J Exp Med 176, 269-274.
Inoue S, Matsumoto T, Iida M, Mizuno M, Kuroki F, Hoshika K, Shimizu M. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol. Sep. 1
Blumberg Richard S.
Fuss Ivan J.
Heller Frank
Strober Warren
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Ouspenski Ilia
The Brigham & Women's Hospital, Inc.
The United States of America as represented by the Department of
LandOfFree
Methods of treating and preventing colitis involving IL-13... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating and preventing colitis involving IL-13..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating and preventing colitis involving IL-13... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223102